Commercial Hybrid Work Models: Structure & Activity

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Improving Hybrid Work Models in Commercial Biopharma Organizations: Optimizing Structure and Activity Performance”

STUDY OVERVIEW

Hybrid work is now the default operating model for commercial biopharma organizations, yet designing structures that consistently deliver performance remains a critical challenge. Leaders must balance flexibility with operational rigor—ensuring collaboration, customer engagement, and field effectiveness without eroding productivity.

This study examines how top companies are structuring hybrid models, allocating time across roles, and optimizing activities for remote versus in-person execution. It analyzes patterns in work distribution, governance of hybrid policies, and the decision frameworks guiding hybrid adoption. The research also identifies which activities perform best remotely and which require in-person engagement—equipping leaders with practical benchmarks to maximize the ROI of office time and sustain performance in a permanently flexible workplace.

KEY TOPICS

Hybrid Work Model Adoption and Governance
Time Spent Remote vs. In-Office by Commercial Function
Activity Suitability for Remote and Hybrid Execution
Role-Specific Guidelines for Hybrid Work

KEY METRICS

Percentage of time spent remote vs. in-office across commercial roles
Primary hybrid work models at benchmarked Commercial organizations
Decision-making authority for hybrid policies
Span of control analysis by seniority
Frequency and effectiveness of commercial activities
Commercial activities most and least suited for remote execution

SAMPLE KEY FINDINGS

Hybrid Model Adoption: Most biopharma organizations follow a 3:2 office-to-home model, balancing flexibility and collaboration.

Commercial Activity Suitability: Activities such as project planning, data analysis, training, and advisory boards are best suited for remote execution.

METHODOLOGY

Best Practices, LLC conducted benchmarking with 9 commercial leaders from 8 biopharma companies, supplemented by interviews to capture deeper insights on hybrid work design and activity optimization.

Industries Profiled:
Pharmaceutical; Biotech; Health Care; Biopharmaceutical; Clinical Research; Laboratories

Companies Profiled:
Bial; Boehringer Ingelheim; Gr�nenthal; Paratek Pharmaceuticals; Pfizer; Sanofi; Takeda; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Improving Hybrid Work Models in Commercial Biopharma Organizations: Optimizing Structure and Activity Performance

ID: 5904

Features:

Pages/Slides: 28

Published: 2025

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6EAD5EE1125FBA6B000258D5B0043B236
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-commercial-hybrid-work-models-structure-activity-optimization?opendocument
18
19opendocument
2018.97.14.83
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB